Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5536MR)

This product GTTS-WQ5536MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5536MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12275MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ7469MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ9251MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2280MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ2724MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ8382MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ933MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ9511MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW